On the stock market since 2001, it operates in the world of health and science. It has 98,200 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 18% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $8.2B would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 11% a year on average.
There is $9.5B in the vault; even if every debt were paid off, $8.2B would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, ANTM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ANTM is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.